Dianthus Therapeutics Reports Q3 2025 Revenue Decline and Increased Net Loss

Dianthus Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing total revenues of $396,000, a significant decrease from $2.2 million in the same period last year. The decline in revenue is attributed to the absence of license revenue from a former related party, which was $2.2 million in the prior year, and a modest $396,000 in new license revenue recognized under the Tenacia Agreements. The company incurred a net loss of $36.8 million for the quarter, compared to a loss of $25.2 million in the third quarter of 2024, reflecting increased operating expenses primarily driven by research and development costs.

For the nine months ending September 30, 2025, Dianthus reported total revenues of $1.8 million, down from $4.9 million in the same period of 2024. The total operating expenses for the nine-month period rose to $110.1 million, up from $74.9 million a year earlier, with research and development expenses accounting for a substantial portion of this increase. The company’s net loss for the nine months was $97.9 million, compared to $56.5 million in the previous year, highlighting the ongoing financial challenges as it advances its clinical programs.

Dianthus has been actively engaged in clinical trials for its lead product candidate, claseprubart, which is being developed for severe autoimmune diseases. The company is currently conducting three mid- to late-stage clinical trials, including the Phase 2 MaGic trial for generalized Myasthenia Gravis, which recently reported positive top-line data. Additionally, the company entered into a License and Collaboration Agreement with Nanjing Leads Biolabs Co. Ltd. for DNTH212, a bifunctional fusion protein, which could further enhance its product pipeline.

As of September 30, 2025, Dianthus had cash, cash equivalents, and investments totaling $555.5 million, a significant increase from $374 million at the end of 2024. This increase is largely due to a public offering that raised $288.4 million in gross proceeds. The company anticipates that its existing cash resources will be sufficient to fund operations into 2028, although it continues to face substantial operating losses and will require additional capital to support ongoing research and development activities.

Looking ahead, Dianthus remains focused on advancing its clinical trials and product development while navigating the uncertainties of the biotechnology market. The company has acknowledged the potential risks associated with its operations, including the need for additional financing and the challenges of obtaining regulatory approvals for its product candidates.